- Home
- ERAS vs AWP Comparison
ERAS vs AWP Comparison
Compare ERAS & AWP Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- ERAS
- AWP
- Stock Information
- Founded
- ERAS 2018
- AWP 2007
- Country
- ERAS United States
- AWP United States
- Employees
- ERAS N/A
- AWP N/A
- Industry
- ERAS Biotechnology: Pharmaceutical Preparations
- AWP Trusts Except Educational Religious and Charitable
- Sector
- ERAS Health Care
- AWP Finance
- Exchange
- ERAS Nasdaq
- AWP Nasdaq
- Market Cap
- ERAS 348.4M
- AWP 342.3M
- IPO Year
- ERAS 2021
- AWP N/A
- Fundamental
- Price
- ERAS $1.39
- AWP $3.92
- Analyst Decision
- ERAS Strong Buy
- AWP
- Analyst Count
- ERAS 6
- AWP 0
- Target Price
- ERAS $4.83
- AWP N/A
- AVG Volume (30 Days)
- ERAS 1.5M
- AWP 331.5K
- Earning Date
- ERAS 05-13-2025
- AWP 01-01-0001
- Dividend Yield
- ERAS N/A
- AWP 12.48%
- EPS Growth
- ERAS N/A
- AWP N/A
- EPS
- ERAS N/A
- AWP N/A
- Revenue
- ERAS N/A
- AWP N/A
- Revenue This Year
- ERAS N/A
- AWP N/A
- Revenue Next Year
- ERAS N/A
- AWP N/A
- P/E Ratio
- ERAS N/A
- AWP N/A
- Revenue Growth
- ERAS N/A
- AWP N/A
- 52 Week Low
- ERAS $1.01
- AWP $3.06
- 52 Week High
- ERAS $3.45
- AWP $4.20
- Technical
- Relative Strength Index (RSI)
- ERAS 54.43
- AWP 52.98
- Support Level
- ERAS $1.06
- AWP $3.84
- Resistance Level
- ERAS $1.47
- AWP $3.95
- Average True Range (ATR)
- ERAS 0.14
- AWP 0.06
- MACD
- ERAS 0.02
- AWP -0.00
- Stochastic Oscillator
- ERAS 70.65
- AWP 61.00
About ERAS Erasca Inc.
Erasca Inc is a clinical-stage precision oncology company singularly focused on discovering, developing, and commercializing therapies for patients with RAS/MAPK pathway-driven cancers. The company's product pipeline includes; Naporafenib, a pan-RAF inhibitor with first-in-class potential in NRASm melanoma, RAS Q61X tissue agnostic solid tumors, and other RAS/MAPK pathway-driven tumors, and ERAS-007 (oral ERK1/2 inhibitor) and ERAS-601 (oral SHP2 inhibitor), which target downstream and upstream nodes, respectively, of the RAS/MAPK pathway.
About AWP abrdn Global Premier Properties Fund of Beneficial Interest
Aberdeen Global Premier Properties Fund is a diversified, closed-end management investment company. Its objective is to seek high current income and capital appreciation. It predominantly invests in equity and debt securities of domestic and foreign issuers which are principally engaged in the real estate industry, real estate financing or control real estate assets. Its portfolio of investments consists securities of Industrial REITs, Retail REITs, Data Center REITs, Health Care REITs and others.